BODIPY FL prazosin

BODIPY FL prazosin is a fluorescent α1-adrenergic antagonist with Ki values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α1-adrenoceptor subtypes[1][2][3].

Product Specifications

CAS Number

[175799-93-6]

UNSPSC

12171500

Target

Adrenergic Receptor

Type

Dye Reagents

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/bodipy-fl-prazosin.html

Purity

99.71

Solubility

DMSO : 12.2 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(CCC1=CC=C2C=C3C(C)=CC(C)=[N]3[B+3]([F-])([N-]21)[F-])N4CCN(CC4)C5=NC6=C(C=C(C(OC)=C6)OC)C(N)=N5

Molecular Formula

C28H32BF2N7O3

Molecular Weight

563.41

References & Citations

[1]Sugawara T, et al. Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci. 2002 Mar 22;70 (18) :2113-24.|[2]Cerveny L, et al. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia. 2006 Mar;47 (3) :461-8.|[3]Fuchs R, et al. α1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca2+ homeostasis in human erythroleukemia cells. Exp Cell Res. 2011 Dec 10;317 (20) :2969-80.